Hydroxyurea and hydroxamic acid derivatives as antitumor drugs Nina SabanMaro Bujak Mini Review 07 April 2009 Pages: 213 - 221
Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells Maiko SuzukiFumiaki ShinoharaHidemi Rikiishi Original Article 02 October 2008 Pages: 223 - 232
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients Pol M. SpecenierTudor CiuleanuJan B. Vermorken Original Article 15 November 2008 Pages: 233 - 241
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study Patrick A. ThompsonGary L. RosnerStacey L. Berg Original Article 20 November 2008 Pages: 243 - 251
Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine William B. ParkerSue C. ShaddixWilliam R. Waud Original Article 11 November 2008 Pages: 253 - 261
Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus Joseph BoniRichat AbbasBruce Hug Original Article 18 November 2008 Pages: 263 - 270
Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy Kouichi MomiyamaHidenari NagaiYasukiyo Sumino Original Article 15 November 2008 Pages: 271 - 277
Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat Premila AbrahamSuganthy Rabi Original Article 18 November 2008 Pages: 279 - 285
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies Monica MitaAlain MitaClaire F. Verschraegen Original Article 25 November 2008 Pages: 287 - 295
Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study Johanna MäenpääArto Leminen Original Article 20 November 2008 Pages: 297 - 300
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer Katia LorizzoNicola FazioFilippo de Braud Original Article 26 November 2008 Pages: 301 - 306
Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro Kate ConnollyRichard MitterSylvie Guichard Original Article 26 November 2008 Pages: 307 - 316
Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study Kyung Hee LeeMin Kyoung KimJun Suk Kim Original Article 26 November 2008 Pages: 317 - 325
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma Youling GongLi RenYuquan Wei Original Article 02 December 2008 Pages: 327 - 333
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates Lindsay B. KilburnPeter L. BonateStacey L. Berg Original Article 29 November 2008 Pages: 335 - 340
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer Satoru TanakaTakehiro NoharaNobuhiko Tanigawa Original Article 28 November 2008 Pages: 341 - 346
A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer Kyoung Ha KimYoung Suk ParkWon Ki Kang Original Article 06 December 2008 Pages: 347 - 353
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin Jong Gwang KimSang Kyun SohnWansik Yu Original Article 04 December 2008 Pages: 355 - 360
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes Takanori IshidaTakayoshi KibaNoriaki Ohuchi Original Article Open access 12 December 2008 Pages: 361 - 369
A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer Hyun Jung KimNam Su LeeDae Sik Hong Original Article 14 January 2009 Pages: 371 - 377
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma Joaquín Casal RubioS. VázquezAs representatives of the Galician Group of Lung Cancer (GGCP in the Spanish acronym) Original Article 13 January 2009 Pages: 379 - 384
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer Gyeong-Won LeeMyung-Hee KangJong-Seok Lee Original Article 23 December 2008 Pages: 385 - 390
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy Nicolas TsavarisAndreas LazarisEfstathios Patsouris Original Article Open access 16 December 2008 Pages: 391 - 398
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy Nicolas TsavarisAndreas LazarisEfstratios Patsouris Erratum 27 March 2009 Pages: 399 - 399
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial Peter SchmidJ. KrockerS. Kümmel Original Article 24 December 2008 Pages: 401 - 406
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer S. H. WatersA. GillibrandTimothy J. Perren Clinical Trial Report 20 May 2009 Pages: 407 - 412
In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B Khalid Abu AjajRalph GraeserFelix Kratz Short Communication 20 February 2009 Pages: 413 - 418
The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells Alessandro AscioneMaurizio CianfrigliaAnna Maria Caccuri Short Communication 15 March 2009 Pages: 419 - 424
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours Edwina N. ScottAnne L. ThomasJohann De Bono Short Communication 12 March 2009 Pages: 425 - 429
Anthocyanins-based drugs for colon cancer treatment: the nutritionist’s point of view Fabio GalvanoFederico SalamonePaola Vitaglione Letter to the Editor 20 May 2009 Pages: 431 - 432
